Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY4257496
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LY4257496 is a **GRPR-targeted radioligand therapy** in clinical development for the treatment of advanced solid tumors, specifically GRPR-positive cancers such as breast, colorectal, prostate, and endometrial carcinomas. It is administered intravenously and functions by targeting the Gastrin-releasing peptide receptor (GRPR), delivering a radioactive payload directly to tumor cells expressing this receptor. LY4257496 is being developed and evaluated by Eli Lilly, both as monotherapy and in combination with standard-of-care anticancer agents. The agent represents a novel therapeutic approach aimed at improving outcomes in cancers with overexpression of GRPR[2][3][5].
- Other names
- LY4257496LY-4257496LY 4257496
02
Targets
GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on LY4257496.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY4257496.